Question · asked by 1 review
TRIFLUOPERAZINE vs LOW‐POTENCY ANTIPSYCHOTIC DRUGS: Acceptability of treatment ‐ leaving the study early
- Population
- patients with schizophrenia
- Intervention
- TRIFLUOPERAZINE
- Comparison
- LOW‐POTENCY ANTIPSYCHOTIC DRUGS
- Outcome
- Acceptability of treatment ‐ leaving the study early
Trifluoperazine showed no clear difference in leaving the study early: 1. Acceptability of treatment ‐ leaving… compared with low‐potency antipsychotic drugs (low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Trifluoperazine vs low‐potency antipsychotic drugs Leaving the study early: 1. Acceptability of treatment ‐ leaving early due to any reason · patients with schizophrenia Trifluoperazine showed no clear difference in leaving the study early: 1. Acceptability of treatment ‐ leaving… compared with low‐potency antipsychotic drugs (low certainty). Trifluoperazine versus low‐potency first‐generation antipsychotic drugs for schizophrenia (2014) · Cochrane Headline outcomes only | RR 1.25 [0.72, 2.17] | 3 studies · 239 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Trifluoperazine versus low‐potency first‐generation antipsychotic drugs for schizophrenia 2014 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.